EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?

Manxi Ge, Yan Zhu, Minjie Wei, Haozhe Piao, Miao He

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2023

DOI: 10.1016/j.bbcan.2023.188996 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023. Verfasst von Manxi Ge und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor D…. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 207 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapies targeting mutations of driver genes in cancer have advanced into clinical trials for a variety of tumors. In glioblastoma (GBM), epidermal growth factor receptor (EGFR) is the most commonly mutated oncogene, and targeting EGFR has been widely investigated as a promising direction. However, the results of EGFR pathway inhibitors have not been satisfactory. Limited blood-brain barrier (BBB) permeability, drug resistance, and pathway compensation mechanisms contribute to the failure of anti-EGFR therapies. This review summarizes recent research advances in EGFR-targeted therapy for GBM and provides insight into the reasons for the unsatisfactory results of EGFR-targeted therapy. By combining the results of preclinical studies with those of clinical trials, we discuss that improved drug penetration across the BBB, the use of multi-target combinations, and the development of peptidomimetic drugs under the premise of precision medicine may be promising strategies to overcome drug resistance in GBM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansErbB ReceptorsOncogenesMutation

Stichwörter der Autor:innen

CombinationsEGFRGlioblastomaStemnessTargeted therapy

Substanzen

ErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, Liaoning Cancer Immune Peptide Drug En…
  • Department of Neurosurgery, Liaoning Cancer Hospital and Institute, Cancer Hospital of China Medical University, Shenyang, China. Electronic address: pzpy@163.com.

Zitieren

APA

Ge, M., Zhu, Y., Wei, M., Piao, H., & He, M. (2023). Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2023.188996

Vancouver

Ge M, Zhu Y, Wei M, Piao H, He M. Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023. doi:10.1016/j.bbcan.2023.188996

BibTeX
@article{Ge2023,
  author = {Ge, Manxi and Zhu, Yan and Wei, Minjie and Piao, Haozhe and He, Miao},
  title = {Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2023},
  doi = {10.1016/j.bbcan.2023.188996}
}
Kostenlos starten →